Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network

被引:27
作者
Balasubramanian, SP
Murrow, S
Holt, S
Manifold, IH
Reed, MW
机构
[1] Univ Sheffield, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
[2] Weston Pk Hosp, N Trent Canc Network, Sheffield S10 2SJ, S Yorkshire, England
[3] Chesterfield & N Derbyshire Gen Hosp, Chesterfield S44 5BL, England
关键词
breast cancer; guidelines; chemotherapy; radiotherapy;
D O I
10.1016/S0960-9776(02)00263-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The North Trent Cancer Network Breast Group in the United Kingdom revised its adjuvant treatment guidelines in breast cancer management in 1998. We aimed to check the compliance to the guidelines, 8 months after their introduction. Data were collected, retrospectively, from the medical records of patients with invasive breast cancer who underwent definitive surgery (in a 3-month period) in different cancer units and the cancer Centre within the North Trent Cancer Network. The overall compliance to treatment guidelines was 82% (90% and 74% for chemotherapy and radiotherapy, respectively), which was similar across the network. In 5% of cases, compliance could not be determined. On case review, 22% of the non-compliant incidents were justified and 16% seemed to be due to variation in guideline interpretation. We discuss the possible reasons for non-compliance and show a need to periodically monitor compliance to adjuvant treatment guidelines. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:136 / 141
页数:6
相关论文
共 39 条
[1]  
ABE O, 1995, NEW ENGL J MED, V333, P1444
[2]  
Abe O, 1998, LANCET, V352, P930
[3]  
[Anonymous], 1992, Lancet, V339, P1
[4]   SUDDEN FALL IN BREAST-CANCER DEATH RATES IN ENGLAND AND WALES [J].
BERAL, V ;
HERMON, C ;
REEVES, G ;
PETO, R .
LANCET, 1995, 345 (8965) :1642-1643
[5]   Principles and guidelines for surgeons - Management of symptomatic breast cancer [J].
BlichertToft, M ;
Smola, MG ;
Cataliotti, L ;
OHiggins, N .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1997, 23 (02) :101-109
[6]  
Carlson RW, 2000, ONCOLOGY-NY, V14, P33
[7]   Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis [J].
Cole, BF ;
Gelber, RD ;
Gelber, S ;
Coates, AS ;
Goldhirsch, A .
LANCET, 2001, 358 (9278) :277-286
[8]   SYSTEMIC THERAPY IN BREAST-CANCER - EFFICACY AND COST-UTILITY [J].
CORRY, JF ;
LONNING, PE .
PHARMACOECONOMICS, 1994, 5 (03) :198-212
[9]   Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution [J].
D'Eredita, G ;
Giardina, C ;
Martellotta, M ;
Natale, T ;
Ferrarese, F .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (05) :591-596
[10]   Implementing guidelines for cancer pain management: Results of a randomized controlled clinical trial [J].
Du Pen, SL ;
Du Pen, AR ;
Polissar, N ;
Hansberry, J ;
Kraybill, BM ;
Stillman, M ;
Panke, J ;
Everly, R ;
Syrjala, K .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :361-370